Supplementary Materials

Topical Peroxisome Proliferator-Activated Receptor Agonist Induces Molecular Alterations Enhancing Barrier Function and Water-Holding Capacity of the Human Stratum Corneum In Vivo

Maxim E. Darvin [1]*, Andrew Salazar [2], Johannes Schleusener [1], Jürgen Lademann [1] and Jörg von Hagen [2,3]*

[1] Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charitéplatz 1, 10117 Berlin, Germany;
[2] Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany;
[3] ryon - GreenTech Accelerator Gernsheim GmbH, Mainzer Str.41, 64579 Gernsheim, Germany
* Correspondence: joerg.von.hagen@merckgroup.com; maxim.darvin@protonmail.com



Figure S1. Chemical structure of oxeglitazar.



Figure S2. Baseline removed Raman spectra of untreated skin (SC, depth ≈7 μm) (black), placebo cream (red) and verum cream (green) in the FP (**A**) and HWN (**B**) ranges.



Figure S3. Triacylglycerol fold change during visit 2 (verum V2 normalised / placebo V2 normalised ratio) normalised to the concentration of short-length chain TG(14:0_14:0_15:0). The horizontal line indicates a 2-fold change between the verum and placebo groups.



Figure S4. Ceramide fold change during visit 2 (verum V2 normalised / placebo V2 normalised ratio) normalised to the concentration of short-length chain Cer(d16:2/18:0). The horizontal line indicates a 2-fold change between the verum and placebo groups.